Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Tianyin Pharmaceutical Co., Inc.Consolidated Balance SheetsDecember 31,
2012Assets(Unaudited)Current assets:Cash and cash equivalents$
35,152,295Restricted cash-3,534,550Accounts receivable, net of allowance for doubtful accounts of $114,006and $113,862 at December 31, 2012 and June 30,
2012, respectively10,500,19911,272,367Inventory6,970,4785,863,013Advance payments -642,075Other current assets451,358436,664Total current assets43,361,68856,900,964Property and equipment, net32,848,63026,458,349Intangibles, net20,584,58920,958,226Advance payments – construction
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2012 PR Newswire.
All rights reserved